Tanke BioSciences Corporation Appoints EFP Rotenberg, LLP as Independent Registered Public Accounting Firm
27 January 2012 - 10:38AM
Marketwired
Tanke BioSciences Corporation (OTCBB: TNBI), a China-based
integrated biotech company that develops, manufactures, and markets
animal feed additives and livestock nutritional products, today
announced its Board of Directors has appointed EFP Rotenberg, LLP
("EFP Rotenberg"), as the company's new independent registered
public accounting firm. As its first task, EFP Rotenberg will
perform Tanke's year-end audit.
Mr. Gilbert Lee, the U.S.-based Chief Financial Officer of Tanke
BioSciences, stated, "Given the growth in our business to date, we
decided Tanke would be best served if, moving forward, we work with
EFP Rotenberg. This partnership reinforces our commitment to the
highest levels of transparency and strong corporate governance.
They have extensive expertise in the China market."
Rochester, New York-based EFP Rotenberg replaces Parker Randall
CF (HK) CPA Limited ("Parker Randall"), whose contract for auditing
services concluded at the end of the 3rd quarter of 2011. The
company chose not to renew that contract. The decision to change
auditors was not the result of any disagreement between the company
and Parker Randall on any matter of accounting principles or
practices, financial statement disclosure, or auditing scope or
procedure.
About Tanke BioSciences Corporation
Tanke BioSciences Corporation, a fully integrated biotech
company, is one of China's leading developers, manufacturers, and
marketers of animal feed additives and livestock nutritional
products. Founded in 1997, Tanke is based in Guangdong Province and
competes in China's $5 billion animal feed additive market. The
company's products directly address China's growing demand for
safe, reasonably priced food. All of Tanke's products are 100% free
of genetically modified organisms (GMOs) and antibiotics.
Cautionary Note Regarding Forward-Looking
Statements
This press release and the statements of representatives of our
officers, directors, employees and representatives related thereto
contain or may contain forward-looking statements which are based
upon the current beliefs and expectations of our management. Such
statements contained in this release are based on management's
exercise of business judgment as well as assumptions made by and
information currently available to management. When used in this
document, the words "guidance," "projects," "may," "could,"
"would," "should," "believes," "expects," "anticipates,"
"estimates," "intends," "plans," "ultimately" and words of similar
import, are intended to identify any forward-looking statements.
The information contained in the forward looking statements is
inherently uncertain, and our actual results may differ materially
due to a number of factors, many of which are beyond our ability to
predict or control, including, among others: (i) changes in the
level of consumer spending or preferences or demand for our
products; (ii) pressures from competition; (iii) our ability to
hire and retain key personnel and our relationship with our
employees; (iv) the performance of our distributors and other key
vendors; (v) effectively carrying out and managing our growth
strategies; (vi) failure to maintain the value and image of our
brand and protect our intellectual property rights; (vii)
seasonality; (viii) costs of materials and labor; (ix) sales,
manufacturing, supply or distribution difficulties or disruptions;
(x) compliance with or changes in Chinese, U.S. or international
laws and regulations; (xi) costs as a result of operating as a
public company; (xii) material weaknesses in internal controls;
(xiii) interest rate and foreign currency risks; (xiv) our ability
to maintain our land use and drug manufacturing rights in China;
(xv) general economic and industry conditions in China and
internationally, and other risks as more fully detailed in our
filings with the Securities and Exchange Commission ("SEC"). Our
filings with the SEC are available at www.sec.gov. You are urged to
consider these factors carefully in evaluating our forward-looking
statements and are cautioned not to place undue reliance on such
forward-looking statements which are qualified in their entirety by
this cautionary statement. The forward-looking statements speak
only as of the date on which they are made, and the company
undertakes no obligation to publicly update such forward-looking
statements to reflect subsequent events or circumstances unless as
required by applicable laws or regulations.
Contacts: Gilbert Lee Chief Financial Officer Tanke
BioSciences Corporation +1 214 906 0065 Michael Draznin Principal
Michael Draznin Consulting +1 917 921 1039
Tanke Biosciences (PK) (USOTC:TNBI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Tanke Biosciences (PK) (USOTC:TNBI)
Historical Stock Chart
From Oct 2023 to Oct 2024